Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right, I seen the report posted here. Horus posted it foe all to see, 76% yesterday, over 50% daily. Shorting should be illegal.
ALYI Secures Investment Partner For African Electric Vehicle Assembly Plant With $20 Million Initial Order
CBD Sector Momentum Squeezing Short Sellers Betting On FDA News
Here we go SS, beware.
That's right, September to be exact. But Texas weather is good to grow year round, plus they have currently 25 green houses, and anticipating adding up to 200 or is it 400 green houses. Plus Kaly exstraction will be based right on the farm. This is going to get real good real soon anytime in my opinion and according to their latest plans. Imo its already in the works now that they passed the law. We should get a huge update here, can't wait.
Last Signal: BUY
Last Pattern: BULLISH DOJI STAR
?
KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10
The KALY PPS experienced a dramatic dip on Monday following Friday’s FDA non-committal comments on CBD and then rebounded on high volume on Tuesday. Now KALY has a buy recommendation and is still below the almost $0.04 high it reached late last year after acquiring the US Patented Cannabis Extraction Process that is currently the center of the company’s growing value. With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders. A $0.10 PPS is not an unreasonable milestone after singing a $5 million CBD extraction contract.
KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum, Hemp4mula available on North American Cannabis Holdings, Inc.’s website www.USMJ.com. KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acer hemp farm.
Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run.
Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report
Last Signal: BUY
Last Pattern: BULLISH DOJI STAR
?
KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10
The KALY PPS experienced a dramatic dip on Monday following Friday’s FDA non-committal comments on CBD and then rebounded on high volume on Tuesday. Now KALY has a buy recommendation and is still below the almost $0.04 high it reached late last year after acquiring the US Patented Cannabis Extraction Process that is currently the center of the company’s growing value. With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders. A $0.10 PPS is not an unreasonable milestone after singing a $5 million CBD extraction contract.
KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum, Hemp4mula available on North American Cannabis Holdings, Inc.’s website www.USMJ.com. KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acer hemp farm.
Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run.
Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report
Last Signal: BUY
Last Pattern: BULLISH DOJI STAR
?
KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10
The KALY PPS experienced a dramatic dip on Monday following Friday’s FDA non-committal comments on CBD and then rebounded on high volume on Tuesday. Now KALY has a buy recommendation and is still below the almost $0.04 high it reached late last year after acquiring the US Patented Cannabis Extraction Process that is currently the center of the company’s growing value. With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders. A $0.10 PPS is not an unreasonable milestone after singing a $5 million CBD extraction contract.
KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum, Hemp4mula available on North American Cannabis Holdings, Inc.’s website www.USMJ.com. KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acer hemp farm.
Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run.
Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report
Were good to grow. Buy them seeds, get them in the ground. Licence only 100 bucks to grow the hemp.
PURA Announces New West Coast Distributor For EVERx CBD Sports Water
Source: InvestorsHub NewsWire
DALLAS, TX -- June 12, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (“PURA”) today announced signing a new West Coast Distributor for its EVERx CBD Sports Water. The distributor is headquartered in Oregon. PURA currently has over $1 million in annualized revenue primarily from the sales of its EVERx CBD Sports Water. Sales of EVERx today come primarily from the South and South West United States. PURA recently announced signing a new East Coast Distributor as well. PURA has announced a 2019 $4 million revenue target.
PURA Announces New West Coast Distributor For EVERx CBD Sports Water
Source: InvestorsHub NewsWire
DALLAS, TX -- June 12, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (“PURA”) today announced signing a new West Coast Distributor for its EVERx CBD Sports Water. The distributor is headquartered in Oregon. PURA currently has over $1 million in annualized revenue primarily from the sales of its EVERx CBD Sports Water. Sales of EVERx today come primarily from the South and South West United States. PURA recently announced signing a new East Coast Distributor as well. PURA has announced a 2019 $4 million revenue target.
Just your daily flipping.
It will bounce up again. Watch
Top dog glad to see ya here.
Bet way, way sooner than that. 30 days at max.
https://www.dallasnews.com/news/texas-legislature/2019/06/11/gov-greg-abbott-signs-law-legalizing-hemp-production-cbd-products-texas
Yahooooooo, yep here we go. Time to make a move NOUV...
ONE HUNDRED ACRES
Very nice find. Thank you
1.5 milly not mentioned in them filings, profits. Way ahead of you bud. Do you own research, unless of course your reason being here is to only spew smack for your own games, which by the way everyone's caught on to your motives.
You find them, all I know they are making revenue and profits with real products as shown and stated numerous times. I'm not here to babysit your antics.
Collecting the green...lmfao
Because me as in I have no problem trading Kaly, on etrade and it TD. I don't have a problem, never did.
Going up.
Spike up comming in. Hit the ask before they try to paint it down.
I think they will post about the Texas hemp legalization, anytime now. What their forward movement will be. The farm their on is already licenced as a nursery, and should be no problem to getting licence for hemp since they are already established in the state. We shall see, but imo they need to take this opportunity with the new law and run with it, now.
Not true, TD and Etrade are trading Kaly. I use both.
Can't open link, please repost.
Hit the news tab, on the board, its there.
Hemp legalization approved in Texas. PURA, KALY, NOUV partners with 100 acre farm, with currently 25 green houses and looking to expand to 400, exstraction being on the farm from KALY, USCH, medical CBD through theses partners and commercial food and product already bringing in profits. Kaly expansion to NY, PURA in Canada, nouv in NY, all cultivating, providing products currently and medical research for future benefits from the partnerships patent exstraction for superior products compared to the competitions.
BS, I trade on TD Ameritrade all the time, etrade I have no problems eighter.
PURA Lining Up For Run From $0.07 To $0.25 On Technical Breakout With Bullish MACD Cross Pushing 200 Day MA
15% up eod my prediction. Watch for the red paint, their gonna try to beat this down eod, hold tight and hit the ask all the way to eod. Big jump tomorrow imo.
PURA popping, big news comming in this trifecta, pura, Kaly, NOUV.
We need a nice close today cause tomorrow is going big time up, up, up.
No we don't know, and eighter do you. You been saying that for a year now and Pitas been producing products and bring in revenue. So take your BS elseware.
Just a little reminder here, thought it would be appropriate along with the Texas hemp growing legalisation. 100 acres with Kaly exstraction.
Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 In Million Pharmaceutical Market Opportunity
Source: InvestorsHub NewsWire
Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 In Million Pharmaceutical Market Opportunity
Dallas, TX -- April 17, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform. KALY owns and operates a patented cannabis extraction process. Following four years of research and development, the company recently executed a strategy to bring the resulting intellectual property (IP) into a public company as part of a plan to capitalize its next stage of development. KALY is that public company platform. In conjunction with that plan, the company has recently disclosed four of its leading research and development initiatives targeting four specific health issues:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
The presentation below and incorporated into the company’s website offers further detail on the company’s progress to date and plans moving forward to commercialize cannabis therapies.
Patented Cannabis Extracts Targeting $170 In Million Pharmaceutical Treatments
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB is biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY, through its subsidiary, NCMB has a deep pipeline of additional cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
$170 Million Cannabis Therapeutics Market Opportunity
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
Cannabis Research Methodology
KALY, through its subsidiary NCMB focuses on the use of specific cannabis extracts alone, and also along with using a proprietary process which combines molecules of already proven therapeutic utility to combat a variety of clinical disorders. In recognition of the need to standardize candidate products and to determine mechanisms for action with scientific credibility, KALY has established collaborations with other companies and with universities to enhance understanding and provide scientific support to the introduction of novel cannabis extract formulations for the consumer marketplace.
KALY has already published its COPD research and initiated a second stage of research and development. Research reports on the first phase of development for KALY’s cannabis compounds for Type 2 Diabetes, Cancer Pain Management and Epilepsy are expected to be published later this year.
To accelerate development, KALY is developing key partners with an emphasis on establishing joint ventures with existing biopharmaceutical companies. The company has a $3.5 million development plan for its next stage of development and management is working diligently to fund that development plan through the capital structure of partner companies.
Beyond The Initial Four Therapies
Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline. KALY’s proprietary extracts have been evaluated in a genomic study where the extracts have exhibited remarkable activity in gene arrays by up or down regulating individual genes by as much as 200 fold. Genes appearing especially sensitive to the introduction of KALY’s cannabis extracts were associated with inflammation, healing and cancer inhibition. The results of the genomic studies have served to initiate planning for a host of additional therapies that can be developed from KALY’s proprietary cannabis extracts.
$1 Million 2019 Revenue Target From Parallel Revenue Strategy
KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. Drawing on KALY’s patented cannabis extraction expertise, Puration’s (USOTC: PURA) EVERx CBD Sports Water is already the leading CBD infused beverage for the sports nutrition market. KALY has also introduced its own CBD confections line, Hemp4mula with CBD infused gum already on the market and gummies on the way. Hemp4mula is expected to be available on the Ecommerce site USMJ.com hosted by North American Cannabis Holdings, Inc. (USOTC: USMJ) (aka USMJ). KALY has also entered into a partnership with Nouveau (USOTC: NOUV), a cannabis cultivation company, with plans to develop a proprietary cannabis cultivar that can further enhance the quality of KALY’s extracts. KALY’s consumer revenue strategy offers a business line that can stand alone, but one that also provides KALY with the long-term staying power to take the necessary time to bring its cannabis extract biopharmaceutical products to market. Currently, KALY management anticipates that its $1 million 2019 revenue goal for its parallel consumersmarket strategy is well within reach.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
The Wales will be comming in, let the news about Texas hemp growing legalization get out there.
That price target don't look so bogus now.
https://www.austinchronicle.com/news/2019-05-31/texas-lawmakers-ok-medical-marijuana-industrial-hemp/
Can't wait to hear from NOUV and Kaly on this one.